FDA approves Abbott's dissolvable stent, Esprit BTK Everolimus Eluting Resorbable Scaffold System, for below-the-knee CLTI treatment.

The FDA has approved Abbott's novel bioresorbable scaffold, Esprit BTK Everolimus Eluting Resorbable Scaffold System, for the treatment of chronic limb-threatening ischemia (CLTI) below-the-knee. The dissolvable stent is the first device authorized by the FDA for the treatment of below-the-knee lesions, following results from the LIFE-BTK trial. The approval marks a significant milestone in the fight against peripheral artery disease below the knee and could lead to improved outcomes for patients worldwide.

April 29, 2024
8 Articles

Further Reading